Timothy P. Walbert joined BioMarin’s Board in February 2025. Mr. Walbert founded Horizon Therapeutics and served as its Chairman, President and Chief Executive Officer until its acquisition by Amgen in 2023. He currently serves as Senior Advisor, Amgen. Prior to Horizon, Mr. Walbert served as President and Chief Executive Officer of IDM Pharma and before IDM held leadership positions at NeoPharm Inc. and Abbott (now AbbVie). He brings more than 30 years of industry experience across a number of pharmaceutical companies, including Pharmacia, Merck, Pfizer and Wyeth Ayerst.

Mr. Walbert serves on the boards of Mirum Pharmaceuticals, Century Therapeutics and Sagimet Biosciences, each public biotechnology companies. Additionally, he serves on the boards of Cour Pharmaceuticals, Odyssey Therapeutics and Latigo Therapeutics (chairman), each private clinical-stage biotechnology companies. He is a member of the National Organization for Rare Disorders (NORD) Advisory Board and the Muhlenberg College Board of Trustees.

Mr. Walbert holds a B.A. in Business from Muhlenberg College in Pennsylvania.